Intech Investment Management LLC Takes $69,000 Position in 2seventy bio, Inc. (NASDAQ:TSVT)

Intech Investment Management LLC bought a new position in 2seventy bio, Inc. (NASDAQ:TSVT) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,658 shares of the company’s stock, valued at approximately $69,000.

Several other hedge funds and other institutional investors have also modified their holdings of TSVT. Marshall Wace LLP grew its position in 2seventy bio by 50.4% in the second quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after acquiring an additional 223,408 shares during the period. Venator Management LLC grew its holdings in shares of 2seventy bio by 49.2% in the 2nd quarter. Venator Management LLC now owns 485,000 shares of the company’s stock worth $1,867,000 after purchasing an additional 160,000 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of 2seventy bio by 5.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company’s stock worth $758,000 after purchasing an additional 10,077 shares during the last quarter. Susquehanna Fundamental Investments LLC boosted its position in 2seventy bio by 39.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock valued at $740,000 after buying an additional 54,076 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in 2seventy bio during the second quarter worth about $385,000. Institutional investors own 93.90% of the company’s stock.

2seventy bio Trading Up 3.5 %

NASDAQ TSVT opened at $3.53 on Monday. The firm has a market cap of $182.11 million, a price-to-earnings ratio of -1.90 and a beta of 1.69. 2seventy bio, Inc. has a 1-year low of $2.29 and a 1-year high of $6.40. The company has a 50 day moving average of $4.39 and a 200-day moving average of $4.38.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.